SPDR S&P Biotech ETF
661 hedge funds and large institutions have $9.04B invested in SPDR S&P Biotech ETF in 2021 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 248 increasing their positions, 178 reducing their positions, and 59 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
20% less capital invested
Capital invested by funds: $11.4B → $9.04B (-$2.32B)
38.46% less ownership
Funds ownership: 156.5% → 118.04% (-38%)
41% less call options, than puts
Call options by funds: $1.39B | Put options by funds: $2.37B
Holders
661
Holding in Top 10
17
Calls
$1.39B
Puts
$2.37B
Top Buyers
| 1 | +$864M | |
| 2 | +$127M | |
| 3 | +$122M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$47.3M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$36.6M |
Top Sellers
| 1 | -$1.27B | |
| 2 | -$808M | |
| 3 | -$664M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$303M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$142M |